Ronda General Mitre, 151
88 articles with Almirall
Almirall, S.A. (ALM ) has launched its second innovation challenge open to worldwide startups who can disrupt the future of digital health. Start-ups can apply between now and October 31 at almiralldigitalgarden.com for a chance to participate in the nine-month accelerator program Digital Garden , powered by Almirall
Almirall: Sustained performance of key growth drivers and excellent progress on pipeline in H1 despite negative impact of COVID-19
Almirall LLC today announced that the FDA approved an important update to the Seysara® label stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
Bioniz Therapeutics, Inc. announced the execution of an option agreement for acquisition by Almirall including its lead candidate, BNZ-1.
Generative modelling artificial intelligence (AI) technology will be used to optimise advanced compounds, to speed up the identification of promising drug candidates for an undisclosed Almirall drug discovery program.
Almirall LLC Announces The Publication Of Long-Term Safety Data For The Use Of Seysara® (Sarecycline) Tablets In Patients 9 Years Of Age And Older
Almirall LLC today announced the publication of long-term safety data from a 40 week, Phase 3 open-label extension study of Seysara® in patients 9 years of age and older. Seysara® is a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne and was approved by the FDA in October of 2018
Athenex, Inc. announced a progress update from partner Almirall on tirbanibulin ointment for the treatment of actinic keratosis
The AlmirallShare open R&D platform aims to establish collaborations to find innovative targets, pathways or therapies in medical dermatology.
Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis
Lebrikizumab is a novel, investigational anti-IL-13 monoclonal antibody under development for the treatment of people with moderate-to-severe atopic dermatitis
Almirall Partners With AARS To Raise Awareness About The Burden Of Disease And Importance Of Education For Dermatology Professionals For National Acne Awareness Month
Almirall announced today their partnership with the American Acne and Rosacea Society to highlight the global health burden of acne during National Acne Awareness Month in June.
Celling Biosciences ("Celling"), based in Austin, Texas, acquired all the assets and stock of ThermiGen, the aesthetic device division of Spanish pharmaceutical leader Almirall.
Almirall Recognized As Distinguished Corporate Leader By American Skin Association - Unveiled Patient-Driven Purpose
Almirall was recognized this week with the Distinguished Corporate Leadership award by the American Skin Association (ASA).
HitGen and Almirall Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest.
Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57.
X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications.
Aqua Pharmaceuticals Assumes Parent Company name and becomes Almirall LLC
lmirall, S.A.(ALM) announced today the finalization of their acquisition of products from Allergan's Medical Dermatology unit in the United States: Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (flurandrenolide).
ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced its participation at the HC Wainwright 20th Annual Global Investment Conference.
Almirall, headquartered in Barcelona, Spain, announced it is buying five dermatology products from Allergan. Those include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline).